title: Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas.
abstract: Replication-competent oncolytic adenoviruses hold considerable promise for treating malignant gliomas. The toxicity of the clinically tested E1B-55 kDa mutant virus is negligible; however, its full clinical potential is still being evaluated. The purpose of the present study is to compare the antiglioma activity in vitro and in vivo between Delta-24, an E1A mutant adenovirus, and RA55, an E1B-55 kDa mutant adenovirus. We selected human glioma cell lines that were tumorigenic in nude mice and express wild-type p53 (U-87 MG, D54 MG) or mutant p53 (U-251 MG, U-373 MG) protein. Our studies demonstrated that Delta-24 induced a more potent antiglioma effect in vitro than RA55. Moreover, Delta-24 replicated markedly more efficiently than RA55 in both wild-type and mutant p53 scenarios. Importantly, direct intratumoral injection of Delta-24, but not RA55, significantly suppresses tumor growth in intracranial (U-87 MG, U-251 MG) or subcutaneous (D54 MG) animal models. Staining for hexon protein detected replicating adenoviruses in xenografts infected with Delta-24, but not with RA55. Collectively, these data indicate that E1A mutant adenoviruses targeting the Rb pathway are more powerful putative agents for antiglioma therapy than E1B mutant adenoviruses, and suggest that E1A mutant adenoviruses should be tested in the clinical setting for patients with malignant gliomas.
authors.affiliation: Brain Tumor Center, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Hong
authors.initials: H
authors.lastname: Jiang
authors.forename: Candelaria
authors.initials: C
authors.lastname: Gomez-Manzano
authors.forename: Ramon
authors.initials: R
authors.lastname: Alemany
authors.forename: Diana
authors.initials: D
authors.lastname: Medrano
authors.forename: Marta
authors.initials: M
authors.lastname: Alonso
authors.forename: B Nebiyou
authors.initials: BN
authors.lastname: Bekele
authors.forename: E
authors.initials: E
authors.lastname: Lin
authors.forename: Charles C
authors.initials: CC
authors.lastname: Conrad
authors.forename: W K Alfred
authors.initials: WK
authors.lastname: Yung
authors.forename: Juan
authors.initials: J
authors.lastname: Fueyo
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D017500:Adenovirus E1A Proteins / Q000172:deficiency / Q000235:genetics*; D017501:Adenovirus E1B Proteins / Q000172:deficiency / Q000235:genetics*; D000260:Adenoviruses, Human / Q000235:genetics*; D000818:Animals; D045744:Cell Line, Tumor; D002470:Cell Survival; D017353:Gene Deletion; D005910:Glioma / Q000378:metabolism / Q000473:pathology* / Q000821:virology*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D014183:Transplantation, Heterologous; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D014779:Virus Replication
chemical_list: D017500:Adenovirus E1A Proteins; D017501:Adenovirus E1B Proteins; D016159:Tumor Suppressor Protein p53
references.citation: Nat Med. 2000 Oct;6(10):1134-9
references.pmid: 11017145
references.citation: Nat Biotechnol. 2000 Jul;18(7):723-7
references.pmid: 10888838
references.citation: Cancer Res. 2002 Nov 1;62(21):6165-71
references.pmid: 12414643
references.citation: Oncogene. 1994 Sep;9(9):2639-47
references.pmid: 8058328
references.citation: Cancer Res. 2001 Apr 1;61(7):2953-60
references.pmid: 11306473
references.citation: Oncogene. 2000 Jan 6;19(1):2-12
references.pmid: 10644974
references.citation: Cancer Res. 1996 Feb 15;56(4):694-9
references.pmid: 8630997
references.citation: J Neurosurg. 2000 Feb;92(2):326-33
references.pmid: 10659021
references.citation: Gene Ther. 2001 Jan;8(2):89-98
references.pmid: 11313778
references.citation: Methods Mol Biol. 1991;7:109-28
references.pmid: 21416352
references.citation: Genes Dev. 2001 Jun 1;15(11):1311-33
references.pmid: 11390353
references.citation: J Virol. 2001 May;75(9):4297-307
references.pmid: 11287579
references.citation: Mol Cell Biol. 1986 Feb;6(2):470-6
references.pmid: 2946932
references.citation: Nat Rev Cancer. 2002 Dec;2(12):938-50
references.pmid: 12459732
references.citation: Cancer Res. 2002 Feb 1;62(3):764-72
references.pmid: 11830531
references.citation: Nat Med. 1997 Jun;3(6):639-45
references.pmid: 9176490
references.citation: Cell. 1978 Jan;13(1):181-8
references.pmid: 620421
references.citation: Virology. 1987 Jan;156(1):107-21
references.pmid: 2949421
references.citation: Science. 1996 Oct 18;274(5286):373-6
references.pmid: 8832876
references.citation: Oncogene. 1995 Aug 3;11(3):467-74
references.pmid: 7630630
references.citation: Exp Cell Res. 1999 Oct 10;252(1):1-12
references.pmid: 10502394
references.citation: Nat Med. 2000 Oct;6(10):1128-33
references.pmid: 11017144
references.citation: Cancer Res. 2002 Oct 15;62(20):5736-42
references.pmid: 12384532
references.citation: Oncogene. 2004 Mar 11;23(10):1821-8
references.pmid: 15014451
references.citation: Cancer Res. 1966 Aug;26(8):1787-800
references.pmid: 4288553
references.citation: EMBO J. 1997 Jul 16;16(14):4276-84
references.pmid: 9250671
references.citation: J Natl Cancer Inst. 2003 May 7;95(9):652-60
references.pmid: 12734316
references.citation: Nat Med. 1998 Dec;4(12):1341-2
references.pmid: 9846551
references.citation: Clin Cancer Res. 2002 Nov;8(11):3348-59
references.pmid: 12429621
references.citation: Mol Ther. 2000 Nov;2(5):485-95
references.pmid: 11082322